Literature DB >> 7094201

Modulation of 5-FU metabolism in human MCF-7 breast carcinoma cells.

P P Major, E M Egan, L Sargent, D W Kufe.   

Abstract

We have previously demonstrated a highly significant relationship (P less than 0.0001) between the incorporation of 5-fluorouracil (5-FU) into total cellular RNA and loss of clonogenic survival of the human MCF-7 breast carcinoma cell line. The present studies explore the applicability of this relationship to MCF-7 cells exposed to 5-FU and modulating agents such as PALA, MTX, and MMPR. PALA treatment produces a minimal increase in the absolute amount of 5-FU incorporated into total cellular RNA, but it results in a three-fold enhancement of the [3H]FU/32P ratio, which measures 5-FU misincorporation into newly synthesized RNA. MTX and MMPR increase intracellular PRPP levels up to four-fold; nevertheless these agents result in only minimal increases in absolute (5-FU)RNA formation. In contrast, the relative incorporation of 5-FU into newly synthesized RNA of MTX- or MMPR-treated cells is increased 2.5-fold. The combination of PALA/MMPR results in a two-fold absolute increase in (5-FU)RNA formation and a nine-fold enhancement of the [3H]FU/32P ratio. Combinations of modulating agents with 5-FU result in more than additive decreases in MCF-7 clonogenic survival. The relationship between 5-FU incorporation into RNA and loss of clonogenic survival was highly significant (P less than 0.0002) when corrected for newly synthesized RNA, while the correlation with absolute amounts of (5-FU)RNA formation was less significant (P less than 0.05). These studies demonstrate that the relationship previously established between (5-FU)RNA formation and loss of clonogenic survival should be corrected for the amount of newly synthesized RNA when 5-FU is combined with modulating agents that alter rates of RNA synthesis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7094201     DOI: 10.1007/BF00292877

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

1.  Enzymatic synthesis and properties of 5-phosphoribosylpyrophosphate.

Authors:  A KORNBERG; I LIEBERMAN; E S SIMMS
Journal:  J Biol Chem       Date:  1955-07       Impact factor: 5.157

2.  Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate.

Authors:  J D Moyer; R E Handschumacher
Journal:  Cancer Res       Date:  1979-08       Impact factor: 12.701

3.  Enhancement of 5-fluorouracil incorporation into human lymphoblast ribonucleic acid.

Authors:  D W Kufe; E M Egan
Journal:  Biochem Pharmacol       Date:  1981-01-15       Impact factor: 5.858

4.  Potentiation of the anti-tumor activity of 5FU by thymidine and its correlation with the formation of (5FU)RNA.

Authors:  S Spiegelman; R Nayak; R Sawyer; R Stolfi; D Martin
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

5.  A phase III study comparing the clinical utility of four regimens of 5-fluorouracil: a preliminary report.

Authors:  F Ansfield; J Klotz; T Nealon; G Ramirez; J Minton; G Hill; W Wilson; H Davis; G Cornell
Journal:  Cancer       Date:  1977-01       Impact factor: 6.860

6.  5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity.

Authors:  D W Kufe; P P Major
Journal:  J Biol Chem       Date:  1981-10-10       Impact factor: 5.157

Review 7.  An overview of thymidine.

Authors:  D S Martin; R L Stolfi; R C Sawyer; R Nayak; S Spiegelman; C W Young; T Woodcock
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

8.  Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism.

Authors:  E Cadman; R Heimer; L Davis
Journal:  Science       Date:  1979-09-14       Impact factor: 47.728

9.  Correlation of cytotoxicity with incorporation of ara-C into DNA.

Authors:  D W Kufe; P P Major; E M Egan; G P Beardsley
Journal:  J Biol Chem       Date:  1980-10-10       Impact factor: 5.157

  9 in total
  5 in total

1.  Effect of Paullinia cupana on MCF-7 breast cancer cell response to chemotherapeutic drugs.

Authors:  Everaldo Hertz; Francine Carla Cadoná; Alencar Kolinski Machado; Verônica Azzolin; Sabrina Holmrich; Charles Assmann; Pauline Ledur; Euler Esteves Ribeiro; Olmiro Cezimbra DE Souza Filho; Maria Fernanda Mânica-Cattani; Ivana Beatrice Mânica DA Cruz
Journal:  Mol Clin Oncol       Date:  2014-10-08

2.  A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.

Authors:  Robert P Whitehead; Jacqueline K Benedetti; James L Abbruzzese; Bach Ardalan; Stephen Williamson; Ellen R Gaynor; Stanley P Balcerzak; John S Macdonald
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

3.  Effect of uridine diphosphoglucose on levels of 5-phosphoribosyl pyrophosphate and uridine triphosphate in murine tissues.

Authors:  J R Colofiore; R C Sawyer; M E Balis; D S Martin
Journal:  Pharm Res       Date:  1989-10       Impact factor: 4.200

4.  Phase-I trial of combination therapy with continuous-infusion MMPR and continuous-infusion 5-FU.

Authors:  W P Peters; G Weiss; D W Kufe
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  Effect of 5-fluorouracil combination therapy on RNA processing in human colonic carcinoma cells.

Authors:  D A Greenhalgh; J H Parish
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.